Increasing evidence suggests that some newly emerged SARS-CoV-2 variants of concern (VoCs) resist neutralization by antibodies elicited by the early-pandemic wild-type virus. We applied neutralization tests to paired recoveree sera ( n = 38) using clinical isolates representing the first wave (D614G), VoC1, and VoC2 lineages (B.1.1.7 and B 1.351). Neutralizing antibodies inhibited contemporary and VoC1 lineages, whereas inhibition of VoC2 was reduced 8-fold, with 50% of sera failing to show neutralization. These results provide evidence for the increased potential of VoC2 to reinfect previously SARS-CoV-infected individuals. The kinetics of NAbs in different patients showed similar decline against all variants, with generally low initial anti-B.1.351 responses becoming undetectable, but with anti-B.1.1.7 NAbs remaining detectable (>20) for months after acute infection.
【저자키워드】 SARS-CoV-2, Immunity, Neutralizing antibodies, 【초록키워드】 Neutralizing antibodies, antibody, neutralization, SARS-CoV-2 variant, variants, Kinetics, B.1.1.7, acute infection, sera, response, neutralization test, VOCs, Patient, Lineage, D614G, clinical isolates, First wave, lineages, NAb, Evidence, neutralization tests, infected individuals, NAbs, wild-type virus, isolate, initial, detectable, inhibited, applied, representing, individuals, elicited, Increasing, was reduced, undetectable, 【제목키워드】 COVID-19, Microneutralization assay, clinical, isolate,